The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    14 injured as escalator reverses at Sunae Station in Bundang

  • 3

    Gov't to launch intensive crackdown against foreigners committing drug crimes

  • 5

    Dog meat traders condemn first lady, animal rights groups' push for ban

  • 7

    Netflix's new original 'Bloodhounds' to deliver cathartic action

  • 9

    INTERVIEWSpaceX's Starlink in Kyiv is wake-up call for Seoul

  • 11

    PHOTOSSubway escalator accident

  • 13

    Billy Graham Seoul Crusade celebrates 50th anniversary

  • 15

    Home gardening boom inspires plant adoption, specialized care services for leafy companions

  • 17

    Yoon's labor reform drive sputters as umbrella union exits talks

  • 19

    White Cube to open space in Seoul

  • 2

    RM to attend Seoul festival to mark BTS' 10th anniv.

  • 4

    Korea falls to Italy in FIFA U-20 World Cup semifinals

  • 6

    Ad or song?: Coca-Cola Zero ad featuring NewJeans becomes marketing blueprint

  • 8

    Robot to conduct orchestra for 1st time in Korea

  • 10

    Dollar remittance, foreign exchange rules to be eased

  • 12

    'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film

  • 14

    Rising minimum wage burdens small biz owners: survey

  • 16

    NATO chief to chair emergency Ukraine meeting over dam

  • 18

    Canada wildfires shroud New York in apocalyptic haze

  • 20

    Korean businesses seek tougher punishments for industrial espionage

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
Sat, June 10, 2023 | 20:02
Tech
Celltrion chairman vows to develop new drugs, initiate M&As
Posted : 2023-03-29 16:13
Updated : 2023-03-30 17:02
Baek Byung-yeul
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
Seo Jung-jin, chairman of Celltrion, speaks during an online press conference, Wednesday. Courtesy of Celltrion
Seo Jung-jin, chairman of Celltrion, speaks during an online press conference, Wednesday. Courtesy of Celltrion

By Baek Byung-yeul

Seo Jung-jin, founder and chairman of Celltrion, vowed to transform the biosimilar maker into a leading new drug maker and launch a series of merger and acquisition (M&A) activities to diversify its business portfolio during an online press conference, Wednesday.

The chairman added that Celltrion will seek advancement into the artificial intelligence (AI) technology-based digital healthcare business to keep pace with trends in the biomedical industry that increasingly utilize emerging digital technologies.

"We are a leader in biosimilars, but we will try to generate 40 percent of the company's sales from our own drugs and 60 percent from biosimilars by 2030," the chairman said. Biosimilar drugs are biological medical products very similar to existing approved products.

The chairman revealed the vision in order to achieve stable growth for the company. "Everyone thinks of Celltrion as a biosimilar company but we expect our Remsima SC drug to be approved as a new drug in the U.S. by October this year. We will also conduct 10 clinical trials for developing new drugs in 2024," Seo said.

Celltrion has expanded partnerships in recent years to secure new drug platform technology. In January, the company became the largest shareholder of the U.K.-based antibody-drug conjugates developer Iksuda Therapeutics through a joint investment with Mirae Asset Group.

The press conference was Seo's first official event a day after he was voted in as a co-chair of the boards of the group's three companies ― Celltrion, Celltrion Pharm and Celltrion Healthcare ― during Tuesday's shareholders' meeting.

In early March, Celltrion announced Seo would return to management, two years after he resigned from management in March 2021, to let the founder serve a critical role in saving the biotechnology group, which has been facing growing business uncertainties.

"We will also try to enter the digital healthcare business based on AI technology. Also when many companies are undervalued, we will actively implement M&As with our surplus cash to expand our business vertically and horizontally," the chairman said.

"We have been interested in the digital healthcare business for a long time. This sector is directed by Seo Jin-seok, chairman of the board of directors of Celltrion. With the development of AI technology, business has become easier. We are in the research stage and plan to launch a separate research center for this business," he said.

The chairman spoke of the pending merger of the three stock market-listed companies ― Celltrion, Celltrion Pharm and Celltrion Healthcare.

"The preparation process for the merge is almost complete. As many shareholders want this, we are looking to finalize the process within up to four months after presenting a milestone for the merger," the chairman said.

In September 2020, Celltrion Group said it would merge the three companies, citing management transparency, strengthening governance and expanding business capabilities.

The chairman also revealed the possibility to establish a drug-manufacturing plant in the U.S. at a time when U.S. President Joe Biden is seeking to strengthen drug manufacturing domestically.

"President Biden is emphasizing the manufacture of raw materials and drugs in the U.S. but no specific plan has been proposed yet. If so, we intend to accept the will of the U.S. administration," Seo said.


Emailbaekby@koreatimes.co.kr Article ListMore articles by this reporter
 
wooribank
Top 10 Stories
1Rising minimum wage burdens small biz owners: survey Rising minimum wage burdens small biz owners: survey
2IPO market regains vigor on bullish KOSPI IPO market regains vigor on bullish KOSPI
3OpenAI explores investment opportunities in Korean startups: Sam Altman OpenAI explores investment opportunities in Korean startups: Sam Altman
4China reaches out to Korean Assembly to counterweigh Yoon's bet on US China reaches out to Korean Assembly to counterweigh Yoon's bet on US
5S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders
6Resurging household loans pose challenge for BOK's rate policy Resurging household loans pose challenge for BOK's rate policy
7SPC bolsters PR activities in US SPC bolsters PR activities in US
8Hyundai Motor partners with Spider-Man animation to envision future mobility Hyundai Motor partners with Spider-Man animation to envision future mobility
9Japanese business leaders pledge to support Busan's Expo bid Japanese business leaders pledge to support Busan's Expo bid
10More foreign language tours will be offered for Cheong Wa Dae More foreign language tours will be offered for Cheong Wa Dae
Top 5 Entertainment News
1China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve
2Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt' Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt'
3[INTERVIEW] CIX talks about team chemistry, youth theme INTERVIEWCIX talks about team chemistry, youth theme
4Netflix's new original 'Bloodhounds' to deliver cathartic actionNetflix's new original 'Bloodhounds' to deliver cathartic action
5'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film 'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group